Weight reduction and maintenance with IQP-PV-101: A 12-week randomized controlled study with a 24-week open label period

Obesity

Volumn 22, Issue 3, 2014, Pages 645-651

  Grube, Barbara ^a   Chong, Wen Fen ^b   Chong, Pee Win ^b   Riede, Linda ^c  

^a Practice for General Medicine   (Germany)

^b InQpharm Europe Ltd   (United Kingdom)

^c Analyze and Realize GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IQP PV 101; PLACEBO; PLANT EXTRACT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CAUCASIAN; CONTROL OF EATING QUESTIONNAIRE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EATING HABIT; FAT MASS; FEMALE; HUMAN; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WEIGHT MAINTENANCE; WEIGHT REDUCTION;

PHASEOLUS VULGARIS;

ADOLESCENT; ADULT; BODY COMPOSITION; BODY MASS INDEX; DIET, REDUCING; DOUBLE-BLIND METHOD; ENERGY INTAKE; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; INTERVENTION STUDIES; MALE; MEALS; MIDDLE AGED; OBESITY; PHASEOLUS; PLANT EXTRACTS; WAIST CIRCUMFERENCE; WEIGHT LOSS; YOUNG ADULT;

EID: 84895834731     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20577     Document Type: Article

References (29)

1. James WPT,. The epidemiology of obesity: The size of the problem. J Intern Med 2008; 263: 336-352.
2. Joliffe D,. Continuous and robust measures of the overweight epidemic: 1971-2000. Demography 2004; 41: 303-314.
3. Berghöfer A, Pischon T, Reinhold T, Apovian MA, Sharma AM, Willich SN,. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200.
4. Asia Pacific Cohort Studies Collaboration. The burden of overweight and obesity in the Asia Pacific region. Obes Rev 2007; 8: 191-196.
5. World Health Organization. World Health Statistics 2012. Geneva: WHO; 2012. pp 36-37.
6. McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G,. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight and obese individuals. Metabolism 2004; 53: 495-499.
7. Wilson PWF, D'Agostino RB, Sullivan L, Parise H, Kannel WB,. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002; 162: 1867-1872.
8. Tsigos C, Hainer V, Basdevant A, et al. Management of obesity in adults: European clinical practice guidelines. Obes Facts 2008; 1: 106-116.
9. Rodgers RJ, Tschöp MH, Wilding JPH,. Anti-obesity drugs: past present and future. Dis Model Mech 2012; 5: 621-626.
10. Moreira FA, Crippa JAS,. The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 2009; 31: 145-153.
11. Williams G,. Withdrawal of sibutramine in Europe. Br J Med 2010; 340: c824.
12. Yun JW,. Possible anti-obesity therapeutics from nature-A review. Phytochemistry 2010; 71: 1625-1641.
13. Drewnowski A, Kurth C, Holden-Wiltse J, Saari J,. Food preferences in human obesity: Carbohydrates versus fats. Appetite 1992; 18: 207-221.
14. Barrett ML, Udani JK,. A proprietary alpha-amylase inhibitor from white bean (Phaseolus vulgaris): A review of clinical studies on weight loss and glycemic control. Nutr J 2011; 10: 24-33.
15. Santimone M, Koukiekolo R, Moreau Y, et al. Porcine pancreatic alpha-amylase inhibition by the kidney bean (Phaseolus vulgaris) inhibitor (alpha-AI1) and structural changes in the alpha-amylase inhibitor complex. Biochim Biophys Acta 2004; 1696: 181-190.
16. Celleno L, Tolaini MV, D'Amore A, Perricone NV, Preuss HG,. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci 2007; 4: 45-52.
17. Wu X, Xu X, Shen J, Perricone N, Preuss H,. Enhanced weight loss from a dietary supplement containing standardized Phaseolus vulgaris extract in overweight men and women. J Appl Res 2010; 10: 73-79.
18. Udani J, Hardy M, Madsen DC,. Blocking carbohydrate absorption and weight loss: A clinical trial using Phase 2™ brand proprietary fractionated white bean extract. Altern Med Rev 2004; 9: 63-69.
19. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
20. Wilcox CS, Oskooilar N, Ericksom JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010: 35: 229-234.
21. EFSA Panel on Dietetic products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA J 2012; 10: 2604 (11 pp).
22. Janssen I, Katzmarzyk PT, Ross R,. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 2004; 79: 347-349.
23. Grievink L, Alberts JF, O'Niel J, Gerstenbluth I,. Waist circumference as a measurement of obesity in the Netherlands Antilles; associations with hypertension and diabetes mellitus. Eur J Clin Nutr 2004; 58: 1159-1165.
24. Stevens VL, Jacobs EJ, Sun J, et al. Weight cycling and mortality in a large prospective US study. Am J Epidemiol 2012; 175: 785-792.
25. Lahti-Koski M, Männistö S, Pietinen P, Vartiainen E,. Prevalence of weight cycling and its relation to health indicators in Finland. Obes Res 2005; 13: 333-311.
26. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein and carbohydrates. N Engl J Med 2009; 360: 859-873.
27. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW,. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194-1199.
28. Lichtman SW, Pisarska K, Berman ER, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med 1992; 327: 1893-1898.
29. Scagliusi FB, Polacow VO, Artioli GG, et al. Selective underreporting of energy intake in women: Magnitude, determinants, and effect of training. J Am Diet Assoc 2003; 103: 1306-1313.